logo
Share SHARE
FONT-SIZE Plus   Neg

Boehringer Ingelheim, Eli Lilly Submit NDA For Empagliflozin - Quick Facts

Boehringer Ingelheim and Eli Lilly and Company (LLY) announced that a New Drug Application for the investigational sodium glucose co-transporter-2 inhibitor empagliflozin was recently submitted to the FDA for the treatment of type 2 diabetes mellitus in adults.

Empagliflozin is a member of the SGLT2 inhibitor class of drugs being investigated for the reduction of blood glucose levels in adults with T2D. The emerging SGLT2 inhibitor class removes excess glucose through the urine by blocking glucose re-absorption in the kidney.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Liliane Bettencourt, the heiress to French cosmetics giant L'Oreal, has died aged 94, her family said Thursday. She was the daughter of Eugène Schueller, founder of the L'Oréal Group. Bettencourt was considered the world's richest woman by both Forbes and the Bloomberg Billionaire Index. Her net worth was estimated at around $44 billion. CVS Pharmacy will limit opioid prescriptions to a seven-day supply for certain conditions, as part of its efforts to fight the national opioid abuse epidemic. CVS Caremark plans to roll out opioid utilization control initiatives for all commercial, health plan, employer and Medicaid clients as of February 1, 2018 unless the client chooses to opt out. Facebook (FB) announced Thursday it has agreed to release advertisements purchased by Russians in an effort to influence last year's election to congressional investigators.
comments powered by Disqus
Follow RTT